Nektar Therapeutics
NKTR
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.27B
Close$
$-29.64
150% downside
Current Fair Value
150% downsideOvervalued by 150% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.27 Billion |
|---|---|
| Enterprise Value | $1.20 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-9.73 |
| Beta | 1.25 |
| Outstanding Shares | 24,736,066 |
Return
| Return on Equity | -27.44% |
|---|---|
| Return on Assets | -20.71% |
| Return on Invested Capital | -19.11% |
Valuation & Multiples
| P/E Ratio | -10.15 |
|---|---|
| PEG | 86.4 |
| Price to Sales | 29.62 |
| Price to Book Ratio | 2.58 |
| Enterprise Value to Revenue | 21.6 |
| Enterprise Value to EBIT | -8.91 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.14 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-1.73
Average shareholder expectationRevenue Estimate
$10.64 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-2.05
Average shareholder expectationRevenue Estimate
$10.38 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4887▼ 38.89% |
|---|---|
| Total Calls | 950,900▲ 43.21% |
| Total Puts | 464,700▼ 20.25% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 131.54%▲ 8.66% |
|---|---|
| Total Invested | $1.92B▲ 162.24% |
| Investors Holding | 219▲ 33.00% |
ESG Score
No data
About Nektar Therapeutics
CEO: Howard Robin